Title
Fosphenytoin pre-medication for pediatric extra-operative electrical stimulation brain mapping
Date Issued
01 February 2018
Access level
metadata only access
Resource Type
journal article
Author(s)
Arya R.
Aungaroon G.
Horn P.S.
Byars A.W.
Greiner H.M.
Mangano F.T.
Holland K.D.
Centro médico del Hospital Infantil de Cincinnati
Publisher(s)
Elsevier B.V.
Abstract
Purpose: We studied the effect of fosphenytoin (FOS) pre-medication on the incidence and thresholds of after-discharges (ADs), seizures, and functional responses during electrical stimulation mapping (ESM). Methods: As individualized by the attending epileptologist, FOS was given intravenously at 2 mg-phenytoin-equivalents (PE)/kg/min or 150 mg-PE/min (whichever slower). Patients who received and did not receive FOS were compared for the incidence and thresholds of ADs, seizures, and functional responses. Results: Before ESM, 40 and 82 patients respectively were pre-medicated/not pre-medicated with FOS. The incidence of ESM-induced seizures was significantly lower in FOS pre-medicated patients (22.5% vs. 42.7%, p = 0.044), whereas temporal language threshold was higher (9.2 vs. 6.5 mA, p = 0.032). FOS was more efficacious in preventing ESM-induced seizures in patients with symptomatogenic zone ipsilateral to the side of ESM. Although FOS dose had no significant effect on minimum language, minimum motor, or AD thresholds; seizure and temporal language thresholds showed trends approaching significance, intersecting at 12.2 mg-PE/kg. The incidence of ESM-induced seizures was significantly lower in those who received FOS at a dose of ≤12 mg/kg (9.1%) compared to those who did not receive any FOS (42.7%, p = 0.046), while the temporal language thresholds were not significantly different (6.3 vs. 6.5 mA, p = 0.897). Conclusions: This study provides class III evidence that FOS pre-medication before ESM decreases the incidence of ESM-induced seizures, but increases temporal language threshold. FOS pre-medication may thus be considered before ESM. Future studies should prospectively verify these observations and characterize dose-response relationships.
Start page
171
End page
176
Volume
140
Language
English
OCDE Knowledge area
Neurología clínica
Scopus EID
2-s2.0-85043303117
PubMed ID
Source
Epilepsy Research
ISSN of the container
0920-1211
Sponsor(s)
RA receives research support from Pediatric Epilepsy Research Foundation (Co-I) and the Maxon Foundation (Co-I) . KDH receives funding from the following NIH grants: R01 NS062756 (PI) , R01 NS062806 (Co-I) , and R01 NS065020 (Co-I) . Other co-authors do not have any pertinent disclosures. Authors wish to acknowledge help in data retrieval from Denise Middler and Jason Buroker. RA wishes to acknowledge support from Susan T. Herman, MD, through American Epilepsy Society’s EpiPORT program.
Sources of information: Directorio de Producción Científica Scopus